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Abstract Phosphatase and tensin homolog deleted on chromo-
some 10 (PTEN) is known to act as a lipid phosphatase hydro-
lyzing phosphatidylinositol (PI)(3,4,5)P3 to PI(4,5)P2. Since the
PI3-kinase product, PI(3,4,5)P3, is an important second mes-
senger leading to the metabolic action of insulin, PTEN func-
tions as a potent negative regulator of insulin signaling and its
gene is one of the possible candidates involved in susceptibility
to the development of type 2 (non-insulin-dependent) diabetes.
In the present study, we investigated the polymorphisms of the
PTEN gene in Japanese patients with type 2 diabetes and non-
diabetic control subjects. We identi¢ed three mutations of the
gene in the type 2 diabetes patients. Among these mutations, the
frequency of the substitution of C with G at position 39
(39CCG) (SNP1), located in the untranslated region of
exon 1, was signi¢cantly higher in type 2 diabetic patients
than in control subjects. In addition, transfection of the
PTEN gene with SNP1 resulted in a signi¢cantly higher ex-
pression level of PTEN protein compared with that of the
wild-type PTEN gene in Cos1 and Rat1 cells. Furthermore,
insulin-induced phosphorylation of Akt in HIRc cells was de-
creased more greatly by transfection of SNP1 PTEN gene than
that of wild-type PTEN gene. These ¢ndings suggest that the
change of C to G at position 39 of the PTEN gene is associated
with the insulin resistance of type 2 diabetes due possibly to a
potentiated hydrolysis of the PI3-kinase product.
6 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Type 2 (non-insulin-dependent) diabetes mellitus is a poly-
genic disorder characterized by reduced insulin secretion and
insulin resistance [1,2]. Although the genetic background is
still poorly understood, genes encoding enzymes or interacting
molecules constituting the insulin signaling pathways are plau-
sible candidates for the insulin resistance [1,2]. The activated
insulin receptor phosphorylates tyrosine residues of insulin
receptor substrates resulting in the association and activation
of phosphatidylinositol (PI)3-kinase [1,2]. PI3-kinase func-
tions as a lipid kinase producing PI(3,4,5)P3 from PI(4,5)P2
in vivo [1^3]. PI(3,4,5)P3 plays an important role as a second
lipid messenger in the performance of insulin signaling leading
to the metabolic e¡ects including glucose uptake and glycogen
synthesis [1^3].
Phosphatase and tensin homolog deleted on chromosome
10 (PTEN) was originally identi¢ed as a candidate tumor
suppressor gene and shares homology with the family of pro-
tein tyrosine phosphatases [4]. Subsequent analysis demon-
strated that PTEN can dephosphorylate PI(3,4,5)P3 at posi-
tion 3 on the inositol ring [5]. Studies with cells derived from
PTEN-de¢cient mice showed increased PI(3,4,5)P3 content
and elevated activity of Akt which is one of the downstream
molecules of PI3-kinase [6]. It is therefore possible that PTEN
modulates insulin signaling by hydrolyzing the PI3-kinase
product PI(3,4,5)P3 to PI(4,5)P2 via its 3P-phosphatase activ-
ity. In fact, overexpression of PTEN inhibited the activation
of Akt in the metabolic action of insulin [7^9]. Insulin-induced
glucose transport was decreased by expression of PTEN in
3T3-L1 adipocytes [7^9]. In addition, expression of PTEN
augmented insulin-induced tyrosine phosphorylation of IRS-
1, and increased the amount of IRS-2 and its association with
PI3-kinase in adipose cells [9^11]. Thus, insulin signaling up-
stream of PI3-kinase is upregulated in response to the hydro-
lysis of the PI3-kinase product by PTEN. Furthermore, the
speci¢c inhibition of PTEN expression by means of an anti-
sense oligonucleotide ameliorated insulin resistance and hy-
perglycemia in diabetic db/db mice [12]. Since these reports
clearly indicate the involvement of PTEN in the insulin signal-
ing system, one can consider that the PTEN gene is a plau-
sible candidate for a causative gene of type 2 diabetes. In the
present study, we examined the association of the PTEN gene
with type 2 diabetes. The polymorphisms of the PTEN gene
throughout the coding regions and exon^intron boundaries
were closely investigated in a type 2 diabetic Japanese popu-
lation.
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2. Materials and methods
2.1. Subjects
107 unrelated subjects with type 2 diabetes (57 men and 50 women,
aged 60.5L 1.2 years, duration of hyperglycemia 12.5L 5.2 years, BMI
23.6L 2.5 kg/m2, HbA1c 7.4 L 1.1%) and 100 non-diabetic control sub-
jects (48 men and 52 women, aged 59.9L 1.7 years, BMI 22.8L 2.1 kg/
m2, HbA1c 5.2L 0.3%) were recruited from the outpatient clinic of the
First Department of Internal Medicine, Toyama Medical and Phar-
maceutical University Hospital, Toyama, Japan. Of the diabetic pa-
tients, 13% were treated with diet, 56% with oral hypoglycemic agents
and 31% with insulin. All the subjects enrolled in this study were
ethnic Japanese. Type 2 diabetes was diagnosed according to the
criteria of the World Health Organization [13]. Before participation,
the purpose and risks of the study were carefully explained both
verbally and in writing, and written informed consent was obtained
from all the participants. The protocol was approved by the ethics
committee of Toyama Medical and Pharmaceutical University.
2.2. Materials
Human crystal insulin was provided by Novo Nordisk Pharma Ltd.
(Copenhagen, Denmark). A monoclonal anti-FLAG antibody (M2)
was purchased from Sigma Chemical Co. (St. Louis, MO, USA). A
monoclonal anti-Erk2 antibody was from Transduction Laboratories
(Lexington, KY, USA). A polyclonal anti-Akt antibody was from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). A polyclonal
anti-Ser473 phosphospeci¢c Akt antibody and a polyclonal anti-Thr308
phosphospeci¢c Akt antibody were from New England Biolabs, Inc.
(Beverly, MA, USA). All other reagents were of analytical grade and
purchased from Sigma or Wako Pure Chemical Industries, Ltd. (Osa-
ka, Japan).
2.3. Genetic analyses
Blood samples were obtained from each subject and genomic DNA
was extracted from peripheral blood leukocytes using a Wizard ge-
nomic DNA puri¢cation kit (Promega, Madison, WI, USA). Muta-
tion analysis of the PTEN gene was conducted using the polymerase
chain reaction-single-stranded conformational polymorphism (PCR-
SSCP) technique and heteroduplex analysis [14]. Primers were de-
signed to include intron^exon boundaries to clarify possible mutations
in splicing sites, based on the sequence reported in DDBJ/EMBL/
GenBank (accession number AF067844). In the design, exons 8 and
9 were divided into two segments. 11 sets of biotinylated primers for
PCR ampli¢cation, which were also used for sequencing, and the
cycling conditions are shown in Table 1. After PCR ampli¢cation,
DNA fragments were electrophoresed at 4 or 25‡C without or with
5% glycerol in 0.5UMDE gel (FMC BioProducts, Rockland, ME,
USA), and visualized with the biotin/streptavidin^alkaline phospha-
tase/PPD system using an Imaging High-Chemilumi-kit (Toyobo,
Osaka, Japan). All SSCP variants were investigated by direct sequenc-
ing using the dGTP BigDye terminator cycle sequence FS ready re-
action kit and an ABI Prism 377 DNA sequencer (PE Applied Bio-
systems, Foster City, CA, USA) after puri¢cation of the PCR
products using a MinElute PCR puri¢cation kit (Qiagen, K.K., To-
kyo, Japan).
2.4. Plasmid construction
C-terminally FLAG-tagged wild-type PTEN and SNP1 PTEN ex-
pression vectors were constructed. In brief, a fragment of PTEN
cDNA was prepared with a 5P-primer containing a HindIII restriction
site (underlined): 5P-AAGCTTTTTTTCTTCAGCCACAGGCTCCC-
AGACATG-3P and a 3P-primer containing a BamHI restriction site
(underlined): 5P-GGATCCAAGACTTTTGTAATTTGTGTATGCT-
GATCTTC-3P based on the sequence reported in DDBJ (accession
number U93051) and subcloned into the HindIII/BamHI site of a
FLAG-tag containing mammalian expression vector pFLAG-CMV-
5b (Sigma Chemical Co.) (pWild-PTEN-FLAG). SNP1 was generated
using the QuickChange site-directed mutagenesis kit (Stratagene, La
Jolla, CA, USA) with two primers: 5P-TTCTTCAGCCACAGGG-
TCCCAGACATGACAGCC-3P (sense) and 5P-GGCTGTCATGTC-
TGGGACCCTGTGGCTGAAGAA-3P (antisense) (pSNP1-PTEN-
FLAG). The appropriate construction of these plasmids was con-
¢rmed by DNA sequencing.
2.5. DNA transfection and Western blotting
Cos1 cells and Rat1 ¢broblasts overexpressing insulin receptors
(HIRc) were maintained in Dulbecco’s modi¢ed Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum (FCS). The cells
were transiently transfected with each plasmid utilizing Transit-LT1
transfection reagent according to the manufacturer’s instructions (Pan
Vera Co., Madison, WI, USA). 48 h after transfection, the cells were
serum-starved for 16 h. The cells were treated with or without 10 nM
insulin at 37‡C for 5 min. The cells were lysed in a bu¡er containing
30 mM Tris, 150 mM NaCl, 10 mM ethylenediamine tetraacetic acid
(EDTA), 0.5% sodium deoxycholate, 1% Triton X-100, 1 mM phen-
ylmethylsulfonyl £uoride, 1 mM Na3VO4, 160 mM sodium £uoride,
10 Wg of aprotinin per ml, 10 WM leupeptin (pH 7.4) for 15 min at
4‡C. The cell lysates were centrifuged to remove insoluble materials.
The supernatants were separated by 7.5% sodium dodecyl sulfate^
polyacrylamide gel electrophoresis (SDS^PAGE) and electrically
transferred onto polyvinylidene di£uoride membranes. After incuba-
tion with the speci¢ed antibody, enhanced chemiluminescence detec-
tion was performed according to the manufacturer’s instructions
(Amersham Pharmacia Biotech, Buckinghamshire, UK) [15].
2.6. Statistical analysis
The data are represented as the meanLS.E.M. P-values were de-
termined by chi-square test (Fisher’s exact test) or Student’s t-test,
and P6 0.05 was considered statistically signi¢cant.
3. Results and discussion
We conducted PCR-SSCP analysis and direct sequencing of
Table 1
Nucleotide sequence of DNA primers used for PCR ampli¢cation of nine exons of PTEN
Forward primer Reverse primer Tm (‡C) Fragment size
(bp)
Exon 1 5P-CTTCTGCCATCTCTCTCCTC-3P 5P-ACTACGGACATTTTCGCATC-3P 58 212
Exon 2 5P-CTGCATATTTCAGATATTTCTTT-3P 5P-CTGTGGCGGAGAAATCTTTTC-3P 58 197
Exon 3 5P-GGTGGCTTTTTGTTTGTTTG-3P 5P-TTAATCGGTTTAGGAATACAA-3P 54 209
Exon 4 5P-ATTCAGGCAATGTTTGTTAGT-3P 5P-TCGATAATCTGGATGACTCA-3P 56 210
Exon 5 5P-GCAACATTTCTAAAGTTACCTA-3P 5P-CTATTTTTCAATAAATTCTCA-3P 54 385
Exon 6 5P-CATAGCAATTTAGTGAAATAACT-3P 5P-GATATGGTTAAGAAAACTGTTC-3P 58 274
Exon 7 5P-CCTGTGAAATAATACTGGTATG-3P 5P-CTCCCAATGAAAGTAAAGTACA-3P 60 229
Exon 8-1 5P-AGGTGACAGATTTTCTTTTTTA-3P 5P-ACTAGATATTCCTTGTCATTAT-3P 56 238
Exon 8-2 5P-GAAGTCTATGTGATCAAGAAA-3P 5P-CAGCTGTACGCCTAGAATTA-3P 56 227
Exon 9-1 5P-TCATATTTGTGGGTTTTCATTT-3P 5P-GTGTCAGAATATCTATAATGAT-3P 56 159
Exon 9-2 5P-TCTGTAACACCAGATGTTAG-3P 5P-TTTTCATGGTGTTTTATCCCT-3P 56 160
Primers for the analyses of the PTEN gene are shown. Exons 8 and 9 were divided into two segments. PCR was carried out in a 50-Wl reaction
mixture, containing 200 ng of template DNA, 1.0 mmol/l of MgCl2, 200 Wmol/l of each dNTP, 200 nmol/l of each primer, and 1.0 U of KOD
plus DNA polymerase with anti-KOD monoclonal antibodies in the bu¡er supplied by the manufacturer (Toyobo, Osaka, Japan). The PCR
conditions were as follows: initial denaturation at 94‡C for 2 min, then 30 cycles of denaturation at 94‡C for 15 s, annealing at Tm35‡C for
30 s, and elongation at 68‡C for 40 s.
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the gene encoding the PTEN protein in 107 patients with type
2 diabetes and 100 control subjects, and identi¢ed three poly-
morphisms. The ¢rst is a substitution of C with G at position
39 (SNP1) which lies in the 5P-untranslated region of exon 1.
The second is a substitution of T with G in intron 5 (SNP2).
The third is a substitution of T with C at position 859 (SNP3)
which lies in exon 8 and causes a missense mutation from Ser
to Pro at position 287 (Table 2). Among these polymor-
phisms, SNP1 was found in 15 (14.0%) diabetic patients and
in ¢ve (5.0%) control subjects, showing a signi¢cant di¡erence
in the frequency of individuals with the mutant allele between
the two groups (P6 0.05). Diabetic patients had both hetero-
zygous and homozygous SNP1 variants, whereas control sub-
jects had the heterozygous but not homozygous variant. The
allele frequencies of the type 2 diabetic patients and non-dia-
betic control subjects were 7.9 and 2.5%, respectively (Table
3). The odds ratio for the frequency of the mutant genotype in
the diabetic group in relation to the control group was 3.10
(the 95% con¢dence interval; 1.08^8.87) (P6 0.05). Since the
allele frequency and the odds ratio for the frequency of mu-
tant genotype were signi¢cantly higher in the diabetic group
than in the control group, the mutation appears to be asso-
ciated with type 2 diabetes in the Japanese population.
The untranslated region from position 39 to 37 is adjacent
to the Kozak sequence (gcca/gccATGg) and gcc at 39 to 37
is also considered part of the consensus sequence for the ini-
tiation of translation [16]. Furthermore, position 39 is in-
cluded in the repetition of G at positions 33, 36 and 39
of the consensus sequence, and the periodicity of G residues
is reported to help ribosomes stay in frame during translation
[17]. Although this 5P-untranslated consensus sequence ap-
pears to be important for translation initiation, the sequence
at this site in wild-type PTEN, ctcccagacATGa, is not typi-
cally optimal [16,17]. By substituting the sequence comprising
this site resulting in a recovery of the periodical occurrence of
the G residue (gtcccagacATGa), SNP1 seems to be more
closely matched to the consensus sequence for the greater
expression of PTEN [16,17]. To examine whether SNP1 a¡ects
the translation of the PTEN mRNA, we constructed a PTEN
cDNA containing the SNP1 substitution. The same amounts
of wild-type PTEN and SNP1 PTEN cDNA were transiently
transfected into Cos1 cells. The expression of PTEN protein
was studied by immunoblot analysis of cell lysates with anti-
FLAG antibody. Interestingly, a greater amount of PTEN
was expressed by transfecting PTEN cDNA bearing SNP1
rather than wild-type PTEN cDNA. By densitometric analy-
sis, the expression of SNP1 PTEN was found to be increased
by 37.2L 8.9% compared to that of wild-type PTEN (Fig. 1).
The increased expression of PTEN was not limited to Cos1
Table 2
Single nucleotide polymorphisms of the PTEN gene in the Japanese population
SNP Location Designationa Change Prevalence (%) P-value
Diabetic patients Control subjects
SNP1 5P-UTRb c. 39CCG non-coding 15/107 (14.0) 5/100 (5.0) 0.034
SNP2 intron 4 IVS 5^11TCG ^ 1/107 (1.0) 0/100 (0.0) N.S.
SNP3 exon 8 c. 859TCC Ser287Pro 1/107 (1.0) 0/100 (0.0) N.S.
The c. preceded the nucleotide number of the reference cDNA sequence (DDBJ accession number U93051), denoting the A of the ATG of the
initiator Met codon as +1. Intronic polymorphism was designated by the intron (IVS: intronic variant sequence) number, a negative number
starting from the G of the acceptor site invariant AG. P-value was determined by chi-square test (Fisher’s exact test).
aDesignation for each SNP was based on the recommendations by the Nomenclature Working Group [24].
b5P-UTR, 5P-untranslated region.
Table 3
Prevalence of SNP1 in type 2 diabetic patients and non-diabetic
control subjects
Type 2 diabetic
patients
Control
subjects
P-value
Number of subjects 107 100
Allele
C/C (WT) 92 95
C/G (hetero) 13 5
G/G (homo) 2 0
Allele frequency (%) 7.9 2.5 0.015
Allele frequency of guanine was calculated by the following formu-
la: allele frequency= ((G/G(homo allele)U2)+(C/G(hetero allele))/
numberU2. P-value was determined by chi-square test (Fisher’s ex-
act test).
Fig. 1. Immunoblot analysis of PTEN protein transiently expressed
in Cos1 cells. A: Cos1 cells were transfected with vacant vector,
pWild-PTEN-FLAG, or pSNP1-PTEN-FLAG. The cell lysates were
separated by 7.5% SDS^PAGE, and immunoblotted with anti-
FLAG antibody or anti-Erk2 antibody. Representative results are
shown. B: The amount of expressed PTEN protein corrected for
the loaded protein amount was quantitated by densitometry. Results
are the meanLS.E.M. of three separate experiments. *P6 0.05 vs.
wild-type (WT)-PTEN expression in Cos1 cells by Student’s t-test.
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cells, because the enhanced expression of PTEN by the SNP1
substitution was also seen in Rat1 ¢broblasts overexpressing
insulin receptors (HIRc cells) (Fig. 2A).
PTEN is known to act as a negative regulator of insulin
signaling by hydrolyzing the PI3-kinase product PI(3,4,5)P3 to
PI(4,5)P2, enhanced expression of PTEN by the SNP1 substi-
tution may lead to diminished insulin signaling distal to PI3-
kinase [7,8]. Akt is a downstream target molecule of PI3-ki-
nase important for the metabolic action of insulin [7,8]. Since
Akt is primarily activated as a result of its phosphorylation,
we examined the e¡ect of wild-type and SNP1 PTEN cDNA
transfection on insulin-induced phosphorylation of Akt [7,8].
Insulin induced phosphorylation of Akt at Ser473 in LacZ-
transfected control HIRc cells. Transfection with wild-type
PTEN cDNA decreased insulin-induced phosphorylation of
Akt by 40.5 L 4.3% in HIRc cells. Importantly, the phosphor-
ylation of Akt was more profoundly reduced by 59.4L 3.1% in
HIRc cells transfected with SNP1 PTEN cDNA (Fig. 2B).
The amount of protein loaded among the samples was con-
¢rmed to be equal by immunoblot analysis with anti-Akt anti-
body (Fig. 2C). In addition, expression of SNP1 PTEN re-
duced insulin-induced phosphorylation of Akt at Thr308 and
activation of Akt signi¢cantly greater than expression of wild-
type PTEN in HIRc cells (data not shown). These results
indicate that insulin resistance may occur, at least in part, at
a step distal to the PI3-kinase in human possessing SNP1
substitution of PTEN. In fact, insulin resistance occurring at
the level of insulin signaling distal to PI3-kinase in human and
animal models of type 2 diabetes has been reported, although
the mechanism involved is not precisely investigated [18^21].
SNP2 and SNP3 were not found in control subjects and
each mutation was only found in one patient of the diabetic
group. It is not clear whether these variants are associated
with type 2 diabetes in the Japanese population. Concerning
the SNP3 (Ser287Pro) variant, PTEN can be phosphorylated
at the Ser/Thr residues of its C-terminal region by the protein
kinase CK2 [22]. The phosphorylation is known to be impor-
tant for the stability of PTEN against its proteasome-medi-
ated degradation [22]. Although the Ser at residue 287 of
PTEN (SNP3) is not found to be critical in the previous re-
ports, it is still possible that the level of expression and/or the
function of PTEN can also be a¡ected by this substitution.
Variants of the coding region in PTEN gene including
SNP1^3 identi¢ed in the present study were not seen in Dan-
ish Caucasian patients with type 2 diabetes [23]. Conversely,
four intronic polymorphisms identi¢ed in the Danish patients
were not found in the current Japanese diabetic patients [23].
Although it would be necessary to examine on a larger scale
of Japanese subjects whether these intronic polymorphisms of
PTEN gene are in fact not seen in Japanese populations, these
di¡erences may arise from a di¡erent genetic background be-
tween the two ethnic groups. Thus, Japanese type 2 diabetic
patients are not particularly obese as shown in the current
study compared to Danish Caucasian diabetic patients [23].
In summary, we have shown an association between the
39CCG polymorphism of the PTEN gene and type 2 dia-
betes in the Japanese population, providing, at least in part,
new insight into the pathogenesis of type 2 diabetes in Japan.
Studies which cover a large number of subjects and other
ethnic populations will be necessary to evaluate the contribu-
tion of SNP1 (39CCG) and SNP3 (Ser287Pro) to the patho-
genesis of insulin resistance and type 2 diabetes.
Fig. 2. E¡ect of PTEN expression on insulin-induced phosphoryla-
tion of Akt in HIRc cells. HIRc cells were transfected with vacant
vector, pWild-PTEN-FLAG, or pSNP1-PTEN-FLAG. The cells
were serum-starved for 16 h, and treated with or without 10 nM in-
sulin for 5 min at 37‡C. The cell lysates were separated by 7.5%
SDS^PAGE, and immunoblotted with anti-FLAG antibody (A),
anti-phosphospeci¢c Akt antibody (B), or anti-Akt antibody (C).
Representative results are shown. The amount of expressed PTEN
and phosphorylated Akt corrected for the loaded protein amount
was quantitated by densitometry. Results are the meanLS.E.M. of
¢ve separate experiments. *P6 0.05 vs. wild-type (WT)-PTEN ex-
pression (A) and *P6 0.05 (B), compared by Student’s t-test.
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